Compare NL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NL | IFRX |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 303.4M |
| IPO Year | 1994 | 2017 |
| Metric | NL | IFRX |
|---|---|---|
| Price | $6.89 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 41.0K | ★ 976.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $158,285,000.00 | N/A |
| Revenue This Year | $9.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | ★ 8.46 | N/A |
| 52 Week Low | $5.04 | $0.80 |
| 52 Week High | $8.60 | $2.95 |
| Indicator | NL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 60.09 |
| Support Level | $5.67 | $2.25 |
| Resistance Level | $8.60 | $2.57 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 77.11 | 59.60 |
NLI Holdings Inc, formerly known as NL Industries Inc, is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.